Preparations based on fibrinogen and sulfated polysaccharides

Patent metadata

Field	Value
Publication number	US-9566364-B2
Application number	US-63662009-A
Country	US
Kind code	B2
Filing date	Dec 11, 2009
Priority date	Dec 11, 2008
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

The present invention provides a preparation comprising fibrinogen and a sulfated polysaccharide as a one component composition or as a kit of parts comprising fibrinogen and sulfated polysaccharide as separated components.
The present invention further provides a fibrin clot like structure obtainable by a defined process, a hemostatic patch, a two-component syringe system and various uses of the described preparations, fibrin clot like structures and patches.

First claim

The invention claimed is:

1. A gel-like aggregate organized as a self-assembled three dimensional structure of adhering vesicles, the three dimensional structure obtained by a process comprising the steps of:
providing a preparation comprising fibrinogen in an amount of 60 mg/ml to 120 mg/ml in a solution and a sulfated polysaccharide;
providing a cation containing solution as a separate component; and
mixing the fibrinogen and sulfated polysaccharide preparation and the cation containing solution so that the gel-like aggregate is obtained,
wherein the process does not involve the action of thrombin,
wherein:
the gel-like aggregate includes the fibrinogen, the sulfated polysaccharide, and the cation, and
the gel-like aggregate does not comprise thrombin.

2. A gel-like aggregate obtained by a process comprising the steps of:
providing a preparation comprising fibrinogen as a solution;
providing a cation containing solution as a separate component together with a sulfated polysaccharide; and
mixing the fibrinogen preparation and the solution containing the cation and the sulfated polysaccharide so that the gel-like aggregate is obtained,
wherein the process does not involve the action of thrombin,
wherein:
the gel-like aggregate includes the fibrinogen, the sulfated polysaccharide, and the cation,
the gel-like aggregate does not comprise thrombin, and
the fibrinogen is present in the gel-like aggregate in a three dimensional arrangement of adhering vesicles.

3. The gel-like aggregate of claim 1 , wherein the sulfated polysaccharide is a fucoidan.

4. The gel-like aggregate of claim 1 , wherein the sulfated polysaccharide is a fucoidan selected from the group consisting of Ascophyllum nodosom LMW fucoidan, Ascophyllum nodosom HMW fucoidan, Fucus vesiculosus fucoidan, Undaria pinnatifida fucoidan, and Laminaria japonica fucoidan.

5. The gel-like aggregate of claim 1 , wherein the cation is selected from the group consisting of calcium, magnesium, barium, and strontium.

6. The gel-like aggregate of claim 1 , wherein the cation is provided from calcium chloride.

7. The gel-like aggregate of claim 1 , wherein the sulfated polysaccharide is selected from the group consisting of glycosaminoglycans (GAGs), heparin-like molecules, sulfatoids, polysulfated oligosaccharides, chondroitin sulfates, dermatan sulfate, fucoidan, pentosan polysulfate (PPS), fucopyranon sulfates, heparinoids, periodate-oxidized heparin (POH), sulfated laminarin (SL), sulfated alginic acid (SAA), sulfated pectin (SP), dextran sulfate (DXS), and heparin-derived oligosaccharides (HDO).

8. The gel-like aggregate of claim 7 , wherein the heparin-like molecules comprise N-acetyl heparin or N-desulfated heparin.

9. The gel-like aggregate of claim 2 , wherein the sulfated polysaccharide is a fucoidan.

10. The gel-like aggregate of claim 2 , wherein the sulfated polysaccharide is a fucoidan selected from the group consisting of Ascophyllum nodosom LMW fucoidan, Ascophyllum nodosom HMW fucoidan, Fucus vesiculosus fucoidan, Undaria pinnatifida fucoidan, and Laminaria japonica fucoidan.

11. The gel-like aggregate of claim 2 , wherein the cation is selected from the group consisting of calcium, magnesium, barium, and strontium.

12. The gel-like aggregate of claim 2 , wherein the cation is provided from calcium chloride.

13. The gel-like aggregate of claim 2 , wherein the sulfated polysaccharide is selected from the group consisting of glycosaminoglycans (GAGs), heparin-like molecules, sulfatoids, polysulfated oligosaccharides, chondroitin sulfates, dermatan sulfate, fucoidan, pentosan polysulfate (PPS), fucopyranon sulfates, heparinoids, periodate oxidized heparin (POH), sulfated laminarin (SL), sulfated alginic acid (SAA), sulfated pectin (SP), dextran sulfate (DXS), and heparin-derived oligosaccharides (HDO).

14. The gel-like aggregate of claim 13 , wherein the heparin-like molecules comprise N-acetyl heparin or N-desulfated heparin.

15. The gel-like aggregate of claim 1 , wherein the cation is at least divalent.

16. The gel-like aggregate of claim 2 , wherein the cation is at least divalent.

17. The gel-like aggregate of claim 2 , wherein the fibrinogen as a solution has a concentration of 60 mg/ml to 120 mg/ml.

18. The gel-like aggregate of claim 1 , wherein the sulfated polysaccharide is present in an amount of 0.01 μg to 300 μg sulfated polysaccharide for each milligram of fibrinogen.

19. The gel-like aggregate of claim 2 , wherein the sulfated polysaccharide is present in an amount of 0.01 μg to 300 μg sulfated polysaccharide for each milligram of fibrinogen.

20. The gel-like aggregate of claim 1 , wherein the sulfated polysaccharide is distributed homogeneously in the three dimensional structure.

21. The gel-like aggregate of claim 2 , wherein the sulfated polysaccharide is distributed homogeneously in the three dimensional structure.

22. The gel-like aggregate of claim 2 , wherein the fibrinogen in the preparation has a concentration of 50 mg/ml.

23. The gel-like aggregate of claim 1 , wherein the gel-like aggregate has a clot like appearance.

24. The gel-like aggregate of claim 2 , wherein the gel-like aggregate has a clot like appearance.

25. The gel-like aggregate of claim 1 , wherein the cation containing solution comprises water.

26. The gel-like aggregate of claim 2 , wherein cation containing solution comprises water.

27. The gel-like aggregate of claim 1 , wherein the solution comprises water.

28. The gel-like aggregate of claim 2 , wherein the solution comprises water.

29. The gel-like aggregate of claim 1 , wherein the cation in the cation containing solution has a concentration of 20 mM.

30. The gel-like aggregate of claim 2 , wherein the cation in the cation containing solution has a concentration of 20 mM.

31. The gel-like aggregate of claim 1 , wherein the sulfated polysaccharide has a concentration from 20 μM to 200 μM in the preparation.

32. The gel-like aggregate of claim 2 , wherein the sulfated polysaccharide has a concentration of 20 μM to 200 μM in the preparation.

Assignees

• Dockal Michael
• Scheiflinger Friedrich
• Hedrich Hans Christian
• Tschetschkowitsch Klaus
• Goppelt Andreas
• Baxter Int
• Baxter Healthcare Sa

Inventors

• Dockal Michael
• Scheiflinger Friedrich
• Hedrich Hans Christian
• Tschetschkowitsch Klaus
• Goppelt Andreas

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61L24/043

  Mixtures of macromolecular materials · CPC title

• A61L2400/04

  Materials for stopping bleeding · CPC title

• A61L24/106 Primary

  Fibrin; Fibrinogen · CPC title